MGF is the splice variant of IGF-1 that muscles produce locally in response to mechanical damage. It activates satellite cells — the stem cells of muscle tissue — triggering repair and growth that cannot be stimulated by systemic IGF-1 alone.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
Mechano Growth Factor (MGF) is produced locally in muscle fibers in response to exercise-induced mechanical strain and micro-damage. It is generated when the IGF-1 gene undergoes differential splicing in mechanically stimulated tissue, producing a unique C-terminal peptide sequence (the E-domain) not present in systemic IGF-1. This local production and the unique E-domain are what make MGF biologically distinct: it does not circulate systemically at meaningful levels — it acts at the site of damage to activate the muscle satellite cells responsible for repair and hypertrophy. PEGylated MGF (PEG-MGF) extends the half-life from minutes to days, making it practical for research use.
Mechanism of Action
MGF acts through two distinct pathways. The unique C-terminal E-domain of MGF activates muscle satellite cells (muscle stem cells) independently of the IGF-1 receptor — triggering proliferation and migration to the site of muscle damage. The IGF-1 receptor binding domain of MGF then drives differentiation and fusion of activated satellite cells into damaged muscle fibers, completing the repair and growth process. This sequential activation-then-differentiation mechanism means MGF provides the initial cellular response to damage, while systemic IGF-1 (or the mature IGF-1 domain of MGF) completes the hypertrophic process. Without adequate satellite cell activation, muscle damage repair is impaired regardless of IGF-1 levels.
Key Research
MGF was identified and characterized by Geoffrey Goldspink at University College London, who published extensively on its role in mechanically induced muscle hypertrophy. Animal studies demonstrated that MGF mRNA expression surges post-exercise and that local injection of MGF-derived peptides produced satellite cell activation and significant muscle hypertrophy without systemic IGF-1 elevation. PEGylation studies confirmed extended half-life while preserving biological activity. Research in aged muscle models showed reduced MGF expression correlates with the impaired muscle repair that characterizes sarcopenia.
200–500 mcg PEG-MGF post-workout; 100–200 mcg standard MGF
Half-Life
Standard MGF: 5–30 minutes; PEG-MGF: 5–7 days
Because standard MGF has a half-life of only 5–30 minutes in serum, PEGylated MGF (PEG-MGF) is the practical research form. PEG-MGF is dosed at 200–400 mcg subcutaneously post-workout, 2–3 times per week, on training days. Standard MGF at 100–200 mcg is used via intramuscular injection (bilaterally into the trained muscle group) immediately post-training. Cycles of 4–6 weeks are typical, with a 4-week break — particularly important because continued satellite cell activation without adequate rest can exhaust the local stem cell pool. PEG-MGF is often combined with IGF-1 LR3 for a comprehensive IGF-1 axis protocol.
Hypertrophy Stack: PEG-MGF 300 mcg post-workout subcutaneously + IGF-1 LR3 40 mcg post-workout for sequential satellite cell activation (MGF) and differentiation (IGF-1 LR3). Use 5 days on, 2 days off, for 4 weeks maximum before a 4-week break. Advanced Muscle Repair: PEG-MGF 200 mcg + CJC-1295/Ipamorelin pre-bed for comprehensive GH-axis + local repair signaling.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
The most clinically relevant concern with MGF research is the theoretical risk of overstimulating satellite cell pools — extended or excessive use may deplete the local satellite cell reservoir, impairing long-term muscle repair capacity. Injection site inflammation is common, particularly with intramuscular injection into trained muscles immediately post-workout when inflammation is already elevated. Hypoglycemia risk is lower than with systemic IGF-1 due to the local mechanism, but blood sugar monitoring is still recommended. Systemic IGF-1 levels do not rise meaningfully with local MGF administration, reducing the IGF-1-related cancer-promotion concerns associated with systemic IGF-1 LR3.
Storage & Handling
Store lyophilized MGF and PEG-MGF at -20°C for long-term storage. At 2–8°C, stable for up to 1 month. Once reconstituted with bacteriostatic water, use within 14 days and keep refrigerated. MGF is sensitive to temperature fluctuations and pH — handle carefully during reconstitution and avoid vigorous mixing.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
